Trilostane

Cat. No.:	HY-14281		
CAS No.:	13647-35-3		
Molecular Formula:	$C_{20}H_{27}NO_3$		
Molecular Weight:	329.43		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 56 mg/mL (169.99 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	3.0355 mL	15.1777 mL	30.3555 mL
	5 mM	0.6071 mL	3.0355 mL	6.0711 mL
	10 mM	0.3036 mL	1.5178 mL	3.0355 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (7.59 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (7.59 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer[1][2].

In Vitro

Trilostane dose- and time-dependently influences pregnenolone metabolism in adrenal cortex[2].
Trilostane selectively inhibits pregnenolone converts to progesterone in adrenal gland[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Trilostane (5.3-50 mg/kg; oral administration, once daily for 3 months) controls pituitary-dependent hyperadreno corticism in dogs[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Dogs with naturally-occurring pituitary-dependent hyperadrenocorticism (PDH)[1]
Dosage:	5.3-50 mg/kg
Administration:	Oral administration; 5.3-50 mg/kg, once daily for 3 months
Result:	Effectively achieved endocrine control with safe effects and free of side-effects.

CUSTOMER VALIDATION

- Leukemia. 2021 Mar 8.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. JA Braddock, et al. Trilostane treatment in dogs with pituitary-dependent hyperadreno-corticism. Veterinary Journal. 10 March 2008.

[2]. Ouschan C, et al. The influence of trilostane on steroid hormone metabolism in canine adrenal glands and corpora lutea-an in vitro study. Vet Res Commun. 2012 Mar;36(1):35-40.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA